

Ghana

Support for Vaccine: Pneumococcal This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Ghana						
2. Vaccine grant number:	12-GHA-08a-Y, 1214-GHA-12C-X, 1517-GHA-12c-X, 1819-GHA-12d-X, 20-GHA-12d-X						
3. Date of Decision Letter:	30 September 2019						
4. Date of the Partnership Framework Agreement:	11 July 2014						
5. Programme title:	New Vaccine Support (NVS), Pneumococcal , Routine						
6. Vaccine type:	Pneumococcal						
7. Requested product presentation and formulation of vaccine:	PCV13, 4 dose(s) per vial, LIQUID						
8. Programme Duration:¹	2012-2020						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2012-2019	2020	2021	2022	2023	2024	Total ²
Programme Budget (US\$)	89,354,034	2,111,000	-	-	-	-	91,465,034
10. Vaccine introduction grant							
	Approval						
	Year	Grant Number					Amount (US\$)
	2012	12-GHA-08a-Y					305,000
	Disbursement						
	Disbursement date						Amount (US\$)
	16 December, 2011						305,000
11. Product switch grant	Not applicable						
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	Type of supplies to be purchased with Gavi funds	2012-2019					2020
	Number of vaccine doses						615,300

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Annual Amounts (US\$)	89,580,980	2,111,000						
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.							
14. Self-procurement:	Not applicable							
15. Co-financing obligations:	According to the co-financing policy, the Country falls within the group: Preparatory transition phase							
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.								
Type of supplies to be purchased with Country funds in each year	2020							
Number of vaccine doses	705,200							
Number of AD syringes	738,600							
Number of re-constitution syringes	-							
Number of safety boxes	8,150							
Value of vaccine doses (US\$)	2,044,514							
Total co-financing payments (US\$) (including freight)	2,103,500							
16. Operational support for campaigns:	Not applicable							
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> 31 March 2020 15 May 2020 </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>			Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
	Due dates							
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020							
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat							

18. Financial clarifications:

Not applicable

19. Other conditions:

Not applicable

Signed by,

On behalf of Gavi



Thabani Maphosa,
Managing Director, Country Programmes
30 September 2019